Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Adicet Bio's operating assets for the quarter that ended in Jun. 2026 was $29.98 Mil. Adicet Bio's operating liabilities for the quarter that ended in Jun. 2026 was $15.17 Mil. Adicet Bio's Total Assets for the quarter that ended in Mar. 2026 was $169.38 Mil. Therefore, Adicet Bio's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2026 was 0.09.
Adicet Bio Scaled Net Operating Assets Related Terms
Adicet Bio Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Adicet Bio's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HX7 vs OKYO, GOSS, ACRV: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, Adicet Bio's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adicet Bio Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adicet Bio's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Adicet Bio's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.09 mean?
Adicet Bio (LTS:0HX7) has a Scaled Net Operating Assets of 0.09 as of Jun. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Adicet Bio and its competitors.
Is Adicet Bio's Scaled Net Operating Assets too high?
Adicet Bio's current Scaled Net Operating Assets is 0.09. Overall, Adicet Bio has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adicet Bio's Scaled Net Operating Assets compare to OKYO and GOSS?
Adicet Bio's Scaled Net Operating Assets of 0.09 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Adicet Bio and its competitors. Adicet Bio's current Scaled Net Operating Assets is 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicet Bio stock overvalued right now?
Based on GuruFocus' analysis, Adicet Bio (LTS:0HX7) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.45, compared to a current price of $8.82 — trading 1860.3% above its estimated fair value. The current Scaled Net Operating Assets is 0.09. Adicet Bio's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Adicet Bio (LTS:0HX7), the current Scaled Net Operating Assets is 0.09 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adicet Bio (LTS:0HX7) Overvalued in 2026?
Based on GuruFocus' analysis, Adicet Bio stock appears to be overvalued.
The current stock price of $8.82 is trading 1860.3% above its estimated GF Value™ of $0.45.
GuruFocus considers Adicet Bio to be Significantly Overvalued.
Key valuation signals for LTS:0HX7:
Scaled Net Operating Assets: 0.09
GF Value™: $0.45 vs. price of $8.82 (1860.3% above fair value)
No single metric tells the full story. See the LTS:0HX7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adicet Bio Inc is a clinical-stage biotechnology company based in the United States that develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Its approach uses off-the-shelf donor-derived gamma delta T cells engineered with chimeric antigen receptors (CARs) to provide durable activity without the need for patient-specific manufacturing. The company's lead candidate, prulacabtagene leucel (prula-cel), is a CD20-targeting CAR gamma delta T cell therapy in development for autoimmune indications. Adicet is also advancing earlier-stage programs, including ADI-212, a gene-edited, armored candidate targeting prostate-specific membrane antigen (PSMA) for oncology. The company's pipeline spans both autoimmune and solid tumor applications. As a clinical-stage business, Adicet does not yet generate product revenue and funds its research and development through equity financings, partnerships, and other capital sources. Its activities are centered on preclinical and clinical development, regulatory interactions, and manufacturing scale-up.
23GF Score
Get the complete analysis for LTS:0HX7
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HX7 has been successfully added to your 
